CRD1601 / Curadev - LARVOL DELTA

Discovery of CRD1601, a potent and selective HPK1 inhibitor with robust in vivo anti-cancer activity (AACR 2024) - "Inhibition of HPK-1 is a promising therapeutic modality that could augment the effects of existing anti-cancer treatments including immunotherapy. CRD1601 is a potent and selective HPK-1 inhibitor with favorable drug like properties that has been selected from a rich portfolio of active compounds and shows promising in vivo activity in tumor models."

Preclinical • Oncology • IFNG • IL2 • LCP2

Discovery of CRD1601, a potent and selective HPK1 inhibitor with robust in vivo anti-cancer activity (ITOC 2024) - "Conclusions HPK-1 inhibition is a promising therapeutic modality that could augment the effects of existing anti-cancer treatments. CRD1601 is a potent and selective HPK-1 inhibitor with favorable drug like properties which shows promising in vivo activity in multiple tumor models as single agent and in combination with existing therapies."

Preclinical • Oncology • IFNG • IL2 • LCP2 • PD-1 • TNFA